Clincosm LogoSign in Get a demo

Integrated Positron Emission Tomography - Computed Tomography (PET-CT) in Patients With Pancreatic Cancer

Sponsor
Asan Medical Center (Other)
Overall Status
Unknown status
CT.gov ID
NCT00885248
Collaborator
(none)
70
Enrollment
1
Location
11
Duration (Months)
6.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

In suspecting pancreatic cancer, dynamic phase pancreatic CT is the most effective tool in diagnosis and staging. In addition, magnetic resolution image, endoscopic ultrasonography, endoscopic retrograde pancreatography, angiography can be performed.

After introduction of functional image, PET has been suggested in the role of diagnosis and staging of pancreatic cancer. Furthermore, recently fused images of PET and CT were available.

In this study, the researchers evaluate the role of integrated PET-CT in patients with pancreatic cancer and analysis the cost-effectiveness of the integrated PET-CT.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Compared to dynamic phase pancreatic CT, integrated PET-CT will be evaluated for sensitivity, specificity and accuracy of diagnosing and staging pancreatic cancer while the gold standard for pancratic cancer is operative specimen. If the operation can't be performed, EUS-FNA of the pancreatic mass or lymph node and additional imaging modality will be preferred to laparotomy.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    70 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Clinical Implication of Integrated PET-CT in the Patients With Pancreatic Cancer
    Study Start Date :
    Jan 1, 2009
    Anticipated Primary Completion Date :
    Nov 1, 2009
    Anticipated Study Completion Date :
    Dec 1, 2009

    Outcome Measures

    Primary Outcome Measures

    1. Staging of pancreatic cancer [6 months after study start]

    Secondary Outcome Measures

    1. Diagnosis of pancreatic cancer [6 months after study start]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Pancreatic mass suspicious of pancreatic cancer

    • No comorbidity, expected life expectancy less than 6 months

    • Consent this study in letter

    Exclusion Criteria:
    • Refuse diagnostic and staging work-up

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Asan Medical Center Seoul Korea, Republic of 138-736

    Sponsors and Collaborators

    • Asan Medical Center

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00885248
    Other Study ID Numbers:
    • 2008-0623
    First Posted:
    Apr 21, 2009
    Last Update Posted:
    Apr 21, 2009
    Last Verified:
    Apr 1, 2009
    Keywords provided by , ,
    pancreatic cancer
    integrated PET-CT
    Additional relevant MeSH terms:
    Pancreatic Neoplasms

    Study Results

    No Results Posted as of Apr 21, 2009